Recent News

By Category: Public Health

New kind of antibiotic may be more effective at fighting tuberculosis, anthrax, and other diseases

(EurekAlert) Diseases such as tuberculosis, anthrax, and shigellosis — a severe food-borne illness — eventually could be treated with an entirely new and more-effective kind of antibiotic, thanks to a team of scientists led by Kenneth Keiler, an associate professor of biochemistry and molecular biology at Penn State University. In a research paper that will Read More »

June 4, 2013
| Filed under North America, Agents & Toxins, Agriculture, Public Health, and Research
Share

Bavarian Nordic’s IMVANEX(r) Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities

(TheWallStreetJournal) Bavarian Nordic A/S (OMX:BAVA) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for IMVANEX(r) for active immunization against smallpox disease for the general adult population, including people with immunodeficiencies (people diagnosed with Read More »

June 3, 2013
| Filed under Europe, North America, Agents & Toxins, Countermeasures, International, Public Health, and Research
Share

Debate rages over merits of GM food | News | Sci-tech | Mail & Guardian

June 2, 2013
| Filed under Public Health
Share

Double dose of antiviral drug offers no added benefit in severe influenza

(EurekAlert) Giving double doses of the antiviral drug oseltamivir, or Tamiflu, offers no clinical or virological advantages over a standard dose for patients admitted to hospital with severe influenza infection, according to a randomised trial published today and funded by the Wellcome Trust, US National Institute of Allergy and Infectious Diseases and the Singapore National Read More »

May 31, 2013
| Filed under North America, Agents & Toxins, Public Health, and Research
Share

FDA Lifts Clinical Hold On PharmAthene’s SparVax(R) Anthrax Vaccine Program

(TheWallStreetJournal) PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on a proposed Phase II study of SparVax(R) , a next generation recombinant anthrax vaccine. “We are very pleased by the Read More »